cancer

Incoming Novartis CEO On $475,000 Cancer Therapy: 'No Question That The List Price Raises Eyebrows'
Incoming Novartis CEO On $475,000 Cancer Therapy: 'No Question That The List Price Raises Eyebrows'
Forbes
Novartis
drug pricing
cancer
Kymriah
Pharma CEOs
Vas Narasimhan
Flag link:
Takeda spins off cancer assets to incubated startup
Takeda spins off cancer assets to incubated startup
Fierce Biotech
Takeda
Chordia Therapeutics
spinoffs
cancer
Flag link:
Cancer Space Update: Label Expansion for Three Major Drugs
Cancer Space Update: Label Expansion for Three Major Drugs
Yahoo/Zacks.com
cancer
labeling
AstraZeneca
Faslodex
Pfizer
Sutent
kidney cancer
Roche
Gazyva
follicular lymphoma
Flag link:
Powerful new cancer drugs are saving lives, but can also ignite diabetes or other autoimmune conditions
Powerful new cancer drugs are saving lives, but can also ignite diabetes or other autoimmune conditions
Science
cancer
checkpoint inhibitors
autoimmune disease
type 1 diabetes
Flag link:
Bayer steps up with $1.55B deal to take a lead role in commercializing Loxo’s cancer drugs
Bayer steps up with $1.55B deal to take a lead role in commercializing Loxo’s cancer drugs
Endpoints
Bayer
Loxo Oncology
cancer
gene therapy
Flag link:
Laws To Control Cancer Drug Costs Don't Help Patients With Highest Expenses
Laws To Control Cancer Drug Costs Don't Help Patients With Highest Expenses
Forbes
cancer
regulatory
drug pricing
Flag link:
Can cancer charity efforts from Roche, Bristol, AbbVie and more boost pharma's reputation?
Can cancer charity efforts from Roche, Bristol, AbbVie and more boost pharma's reputation?
Fierce Pharma
charity
Roche
Bristol-Myers Squibb
AbbVie
cancer
reputation
Flag link:
5 Game-Changing Cancer Drug Innovations Being Developed Right Now
5 Game-Changing Cancer Drug Innovations Being Developed Right Now
Motley Fool
cancer
cancer immunotherapies
CAR-T
T-cell receptors
TCR therapeutics
IDO inhibitors
epigenetics
Flag link:
Most new cancer meds haven't proved they can improve or extend lives: study
Most new cancer meds haven't proved they can improve or extend lives: study
Fierce Pharma
cancer
oncology
Merck
Keytruda
Roche
Tecentriq
Flag link:
The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
Motley Fool
cancer
cancer immunotherapies
Opdivo
Bristol-Myers Squibb
Keytruda
Merck
Yervoy
Flag link:
Cancer patients know immuno-oncology and top drugs, but lack details: study
Cancer patients know immuno-oncology and top drugs, but lack details: study
Fierce Pharma
patients
cancer
immuno-oncology
Opdivo
Keytruda
Merck
Bristol-Myers Squibb
Flag link:
Big pharma stands to make hundreds of billions of dollars from a handful of medical conditions
Big pharma stands to make hundreds of billions of dollars from a handful of medical conditions
Motley Fool
Big Pharma
viral hepatitis
respiratory disease
autoimmune disease
cardiovascular disease
pain
diabetes
cancer
Flag link:
WHO to Launch Pilot to Prequalify Biosimilars
WHO to Launch Pilot to Prequalify Biosimilars
RAPS.org
WHO
biosimilars
cancer
Flag link:
Daiichi Sankyo hands off cancer drug to Boston Pharma
Daiichi Sankyo hands off cancer drug to Boston Pharma
BioPharma Dive
Boston Pharmaceuticals
Daiichi Sankyo
DS-5010
cancer
Flag link:
Nanotech, immunotherapy combo vaccinates mouse against cancer
Nanotech, immunotherapy combo vaccinates mouse against cancer
Drug Delivery Business News
nanotech
immunotherapy
vaccines
cancer
Flag link:
New study of FDA cites the flaws behind rapid-fire cancer drug OKs
New study of FDA cites the flaws behind rapid-fire cancer drug OKs
Endpoints
FDA
drug approvals
cancer
oncology
Flag link:
A Cancer Conundrum: Too Many Drug Trials, Too Few Patients
A Cancer Conundrum: Too Many Drug Trials, Too Few Patients
NY Times, NY
cancer
oncology
clinical trials
patients
Flag link:
Ending the era of $100,000 cancer drugs
Ending the era of $100,000 cancer drugs
Pharmafile
cancer
drug pricing
oncology
Flag link:
Making the Promise of Immunotherapeutics into Reality
Making the Promise of Immunotherapeutics into Reality
Elsevier
immunotherapy
cancer
Flag link:
GSK CEO Walmsley is reorganizing R&D, dropping drugs and adding a new focus on cancer research
GSK CEO Walmsley is reorganizing R&D, dropping drugs and adding a new focus on cancer research
Endpoints
GSK
reorganization
Emma Walmsley
Pharma CEOs
R&D
cancer
Flag link:

Pages